These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9175050)

  • 1. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats.
    Rosenbaum DP; Holmes-Farley SR; Mandeville WH; Pitruzzello M; Goldberg DI
    Nephrol Dial Transplant; 1997 May; 12(5):961-4. PubMed ID: 9175050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers.
    Burke SK; Slatopolsky EA; Goldberg DI
    Nephrol Dial Transplant; 1997 Aug; 12(8):1640-4. PubMed ID: 9269642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.
    Goldberg DI; Dillon MA; Slatopolsky EA; Garrett B; Gray JR; Marbury T; Weinberg M; Wombolt D; Burke SK
    Nephrol Dial Transplant; 1998 Sep; 13(9):2303-10. PubMed ID: 9761513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency.
    Nagano N; Miyata S; Obana S; Ozai M; Kobayashi N; Fukushima N; Burke SK; Wada M
    Nephrol Dial Transplant; 2001 Sep; 16(9):1870-8. PubMed ID: 11522872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
    Chertow GM; Burke SK; Lazarus JM; Stenzel KH; Wombolt D; Goldberg D; Bonventre JV; Slatopolsky E
    Am J Kidney Dis; 1997 Jan; 29(1):66-71. PubMed ID: 9002531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder.
    Nagano N; Miyata S; Obana S; Eto N; Fukushima N; Burke SK; Wada M
    Nephron; 2001 Nov; 89(3):321-8. PubMed ID: 11598397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency.
    Nagano N; Miyata S; Obana S; Kobayashi N; Fukushima N; Burke SK; Wada M
    Nephrol Dial Transplant; 2003 Oct; 18(10):2014-23. PubMed ID: 13679475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.
    Taniguchi K; Kakuta H
    Eur J Pharmacol; 2015 Nov; 766():129-34. PubMed ID: 26452517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renagel: reducing serum phosphorus in haemodialysis patients.
    Burke SK
    Hosp Med; 2000 Sep; 61(9):622-7. PubMed ID: 11048603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphate binder usage in kidney failure patients.
    Bleyer AJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):941-7. PubMed ID: 12783590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renagel: a new and different phosphate binder.
    Ramsdell R
    ANNA J; 1999 Jun; 26(3):346-7. PubMed ID: 10633608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of phosphonoformic acid and renagel on renal type IIa sodium-dependent phosphate cotransporter mRNA expression in hyperphosphatemia rats.
    Zeng M; Wang X; Wang X; Zhao X
    Ren Fail; 2012; 34(3):358-63. PubMed ID: 22260362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients.
    Chertow GM; Dillon M; Burke SK; Steg M; Bleyer AJ; Garrett BN; Domoto DT; Wilkes BM; Wombolt DG; Slatopolsky E
    Clin Nephrol; 1999 Jan; 51(1):18-26. PubMed ID: 9988142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.
    Nagano N; Miyata S; Abe M; Kobayashi N; Wakita S; Yamashita T; Wada M
    Kidney Int; 2006 Feb; 69(3):531-7. PubMed ID: 16395276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB; Smeeding JE; Brook RA
    Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats.
    King AJ; Kohler J; Fung C; Jiang Z; Quach A; Kumaraswamy P; Chertow GM; Rosenbaum DP
    Am J Physiol Renal Physiol; 2021 Jan; 320(1):F133-F144. PubMed ID: 33283643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.